270 related articles for article (PubMed ID: 35347225)
1. Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension.
Guillén-Del-Castillo A; Meseguer ML; Fonollosa-Pla V; Giménez BS; Colunga-Argüelles D; Revilla-López E; Rubio-Rivas M; Ropero MJC; Argibay A; Barberá JA; Salas XP; Meñaca AM; Vuelta ABM; Padrón AL; Comet LS; Morera JAD; González-Echávarri C; Mombiela T; Ortego-Centeno N; González MM; Tolosa-Vilella C; Blanco I; Subías PE; Simeón-Aznar CP; ;
Sci Rep; 2022 Mar; 12(1):5289. PubMed ID: 35347225
[TBL] [Abstract][Full Text] [Related]
2. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis.
Moinzadeh P; Bonella F; Oberste M; Weliwitage J; Blank N; Riemekasten G; Müller-Ladner U; Henes J; Siegert E; Günther C; Kötter I; Pfeiffer C; Schmalzing M; Zeidler G; Korsten P; Susok L; Juche A; Worm M; Jandova I; Ehrchen J; Sunderkötter C; Keyßer G; Ramming A; Schmeiser T; Kreuter A; Lorenz HM; Hunzelmann N; Kreuter M
Chest; 2024 Jan; 165(1):132-145. PubMed ID: 37582424
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
[TBL] [Abstract][Full Text] [Related]
4. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
Launay D; Humbert M; Berezne A; Cottin V; Allanore Y; Couderc LJ; Bletry O; Yaici A; Hatron PY; Mouthon L; Le Pavec J; Clerson P; Hachulla E
Chest; 2011 Oct; 140(4):1016-1024. PubMed ID: 21474572
[TBL] [Abstract][Full Text] [Related]
6. Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.
Yuan YP; Yuan P; Su YL; Jiang R; Zhang R; He J; Qiu HL; Luo CJ; Liu JM; Gong SG; Wang L; Zhao QH
Clin Rheumatol; 2022 Jun; 41(6):1675-1686. PubMed ID: 35099674
[TBL] [Abstract][Full Text] [Related]
7. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort.
Noviani M; Saffari SE; Tan JL; Yip JWL; Teng GG; Law WG; Chan GYL; Santosa A; Lim AYN; Hong C; Ng SA; Tay ELW; Ruan W; Yap J; Low AHL
Semin Arthritis Rheum; 2020 Jun; 50(3):473-479. PubMed ID: 31810742
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and survival of pulmonary arterial hypertension with or without interstitial lung disease in systemic sclerosis.
Fairley JL; Hansen D; Ross L; Proudman S; Sahhar J; Ngian GS; Walker J; Host LV; Morrisroe K; Apostolopoulous D; Ferdowsi N; Wilson M; Tabesh M; Stevens W; Nikpour M;
Arthritis Res Ther; 2023 May; 25(1):77. PubMed ID: 37173780
[TBL] [Abstract][Full Text] [Related]
9. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.
Volkmann ER; Saggar R; Khanna D; Torres B; Flora A; Yoder L; Clements PJ; Elashoff RM; Ross DJ; Agrawal H; Borazan N; Furst DE; Saggar R
Arthritis Rheumatol; 2014 Jul; 66(7):1900-8. PubMed ID: 24729406
[TBL] [Abstract][Full Text] [Related]
10. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE
Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
[TBL] [Abstract][Full Text] [Related]
11. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
[TBL] [Abstract][Full Text] [Related]
12. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies.
Le Pavec J; Girgis RE; Lechtzin N; Mathai SC; Launay D; Hummers LK; Zaiman A; Sitbon O; Simonneau G; Humbert M; Hassoun PM
Arthritis Rheum; 2011 Aug; 63(8):2456-64. PubMed ID: 21538327
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary survival study in 91 patients with systemic sclerosis.
Poormoghim H; Lakeh MM; Mohammadipour M; Talehy-Moineddin S; Sodagari F
Rheumatol Int; 2011 Dec; 31(12):1577-82. PubMed ID: 20496069
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up.
Vilela VS; Dias MM; Salgado ÂA; da Silva BRA; Lopes AJ; Bessa EJC; Bruno LP; da Costa CH; Levy RA; Rufino R
BMC Pulm Med; 2021 Jul; 21(1):251. PubMed ID: 34325685
[TBL] [Abstract][Full Text] [Related]
15. Relevance of partitioning DLCO to detect pulmonary hypertension in systemic sclerosis.
Sivova N; Launay D; Wémeau-Stervinou L; De Groote P; Remy-Jardin M; Denis G; Lambert M; Lamblin N; Morell-Dubois S; Fertin M; Lefevre G; Sobanski V; Le Rouzic O; Hatron PY; Wallaert B; Hachulla E; Perez T
PLoS One; 2013; 8(10):e78001. PubMed ID: 24205063
[TBL] [Abstract][Full Text] [Related]
16. Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Comparison of Demographic, Hemodynamic, and MRI Characteristics and Outcomes.
Ramjug S; Hussain N; Hurdman J; Billings C; Charalampopoulos A; Elliot CA; Kiely DG; Sabroe I; Rajaram S; Swift AJ; Condliffe R
Chest; 2017 Jul; 152(1):92-102. PubMed ID: 28223154
[TBL] [Abstract][Full Text] [Related]
17. [The clinical characteristics of systemic sclerosis-related pulmonary arterial hypertension].
Wang H; Tian Z; Liu Y; Li M; Wang Q; Zeng X; Fang Q
Zhonghua Nei Ke Za Zhi; 2014 May; 53(5):390-3. PubMed ID: 25146407
[TBL] [Abstract][Full Text] [Related]
18. Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension.
Argula RG; Karwa A; Lauer A; Gregg D; Silver RM; Feghali-Bostwick C; Schanpp LM; Egbert K; Usher BW; Ramakrishnan V; Hassoun PM; Strange C
Ann Am Thorac Soc; 2017 May; 14(5):682-689. PubMed ID: 28282243
[TBL] [Abstract][Full Text] [Related]
19. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry.
Chung L; Domsic RT; Lingala B; Alkassab F; Bolster M; Csuka ME; Derk C; Fischer A; Frech T; Furst DE; Gomberg-Maitland M; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TA; Molitor JA; Preston IR; Schiopu E; Shapiro L; Silver R; Simms R; Varga J; Gordon JK; Steen VD
Arthritis Care Res (Hoboken); 2014 Mar; 66(3):489-95. PubMed ID: 23983198
[TBL] [Abstract][Full Text] [Related]
20. The soluble receptor for advanced glycation end products is potentially predictive of pulmonary arterial hypertension in systemic sclerosis.
Atzeni IM; Al-Adwi Y; Doornbos-van der Meer B; Roozendaal C; Stel A; van Goor H; Gan CT; Dickinson M; Timens W; Smit AJ; Westra J; Mulder DJ
Front Immunol; 2023; 14():1189257. PubMed ID: 37409127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
